|
1
|
Bertuccio P, Turati F, Carioli G,
Rodriguez T, La Vecchia C, Malvezzi M and Negri E: Global trends
and predictions in hepatocellular carcinoma mortality. J Hepatol.
67:302–309. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cazzagon N, Trevisani F, Maddalo G,
Giacomin A, Vanin V, Pozzan C, Poggio PD, Rapaccini G, Nolfo AM,
Benvegnù L, et al Italian Liver Cancer (ITA.LI.CA) Group, : Rise
and fall of HCV-related hepatocellular carcinoma in Italy: A
long-term survey from the ITA.LI.CA centres. Liver Int.
33:1420–1427. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Taura N, Fukushima N, Yastuhashi H, Takami
Y, Seike M, Watanabe H, Mizuta T, Sasaki Y, Nagata K, Tabara A, et
al: The incidence of hepatocellular carcinoma associated with
hepatitis C infection decreased in Kyushu area. Med Sci Monit.
17:PH7–PH11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marot A, Henrion J, Knebel JF, Moreno C
and Deltenre P: Alcoholic liver disease confers a worse prognosis
than HCV infection and non-alcoholic fatty liver disease among
patients with cirrhosis: An observational study. PLoS One.
12:e01867152017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hamed MA and Ali SA: Non-viral factors
contributing to hepatocellular carcinoma. World J Hepatol.
5:311–322. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hemkens LG, Grouven U, Bender R, Günster
C, Gutschmidt S, Selke GW and Sawicki PT: Risk of malignancies in
patients with diabetes treated with human insulin or insulin
analogues: A cohort study. Diabetologia. 52:1732–1744. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oda K, Uto H, Mawatari S and Ido A:
Clinical features of hepatocellular carcinoma associated with
nonalcoholic fatty liver disease: A review of human studies. Clin J
Gastroenterol. 8:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamada S, Kawaguchi A, Kawaguchi T,
Fukushima N, Kuromatsu R, Sumie S, Takata A, Nakano M, Satani M,
Tonan T, et al: Serum albumin level is a notable profiling factor
for non-B, non-C hepatitis virus-related hepatocellular carcinoma:
A data-mining analysis. Hepatol Res. 44:837–845. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Degos F, Christidis C, Ganne-Carrie N,
Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M and
Chevret S: Hepatitis C virus related cirrhosis: Time to occurrence
of hepatocellular carcinoma and death. Gut. 47:131–136. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Minami T, Tateishi R, Shiina S, Nakagomi
R, Kondo M, Fujiwara N, Mikami S, Sato M, Uchino K, Enooku K, et
al: Comparison of improved prognosis between hepatitis B- and
hepatitis C-related hepatocellular carcinoma. Hepatol Res.
45:E99–E107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hashimoto M, Tashiro H, Kobayashi T,
Kuroda S, Hamaoka M and Ohdan H: Clinical characteristics and
prognosis of non-B, non-C hepatocellular carcinoma: The impact of
patient sex on disease-free survival - A retrospective cohort
study. Int J Surg. 39:206–213. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hiwatashi K, Ueno S, Sakoda M, Iino S,
Minami K, Yamasaki Y, Okubo K, Noda M, Kurahara H, Mataki Y, et al:
Problems of long survival following surgery in patients with
nonBNonC-HCC: Comparison with HBV and HCV related-HCC. J Cancer.
6:438–447. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Radice R, Ramsahai R, Grieve R, Kreif N,
Sadique Z and Sekhon JS: Evaluating treatment effectiveness in
patient subgroups: A comparison of propensity score methods with an
automated matching approach. Int J Biostat. 8:252012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Desbordes P, Ruan S, Modzelewski R, Pineau
P, Vauclin S, Gouel P, Michel P, Di Fiore F, Vera P and Gardin I:
Predictive value of initial FDG-PET features for treatment response
and survival in esophageal cancer patients treated with
chemo-radiation therapy using a random forest classifier. PLoS One.
12:e01732082017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Diouf M, Filleron T, Pointet AL,
Dupont-Gossard AC, Malka D, Artru P, Gauthier M, Lecomte T,
Aparicio T, Thirot-Bidault A, et al: Prognostic value of
health-related quality of life in patients with metastatic
pancreatic adenocarcinoma: A random forest methodology. Qual Life
Res. 25:1713–1723. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mohammadzadeh F, Noorkojuri H,
Pourhoseingholi MA, Saadat S and Baghestani AR: Predicting the
probability of mortality of gastric cancer patients using decision
tree. Ir J Med Sci. 184:277–284. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Min KW, Kim DH, Son BK, Kim EK, Ahn SB,
Kim SH, Jo YJ, Park YS, Seo J, Oh YH, et al: Invasion depth
measured in millimeters is a predictor of survival in patients with
distal bile duct cancer: Decision tree approach. World J Surg.
41:232–240. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kokudo N, Hasegawa K, Akahane M, Igaki H,
Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, et al:
Evidence-based clinical practice guidelines for hepatocellular
carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC
Guidelines). Hepatol Res. 45:452015. View Article : Google Scholar
|
|
19
|
Liver Cancer Study Group of Japan, . The
general rules for the clinical and pathological study of primary
liver cancer. Jpn J Surg. 19:98–129. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kawaoka T, Aikata H, Kobayashi T, Uchikawa
S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, et al:
Comparison of hepatic arterial infusion chemotherapy between
5-fluorouracil-based continuous infusion chemotherapy and low-dose
cisplatin monotherapy for advanced hepatocellular carcinoma.
Hepatol Res. 48:1118–1130. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saeki I, Yamasaki T, Maeda M, Hisanaga T,
Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T and Sakaida
I: Evaluation of the ‘assessment for continuous treatment with
hepatic arterial infusion chemotherapy’ scoring system in patients
with advanced hepatocellular carcinoma. Hepatol Res. 48:E87–E97.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsunematsu S, Suda G, Yamasaki K, Kimura
M, Takaaki I, Umemura M, Ito J, Sato F, Nakai M, Sho T, et al:
Combination of neutrophil-to-lymphocyte ratio and early
des-γ-carboxyprothrombin change ratio as a useful predictor of
treatment response for hepatic arterial infusion chemotherapy
against advanced hepatocellular carcinoma. Hepatol Res. 47:533–541.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakano M, Niizeki T, Nagamatsu H, Tanaka
M, Kuromatsu R, Satani M, Okamura S, Iwamoto H, Shimose S, Shirono
T, et al Kurume Liver Cancer Study Group of Japan, : Clinical
effects and safety of intra-arterial infusion therapy of cisplatin
suspension in lipiodol combined with 5-fluorouracil versus
sorafenib, for advanced hepatocellular carcinoma with macroscopic
vascular invasion without extra-hepatic spread: A prospective
cohort study. Mol Clin Oncol. 7:1013–1020. 2017.PubMed/NCBI
|
|
24
|
Cabibbo G, Enea M, Attanasio M, Bruix J,
Craxì A and Cammà C: A meta-analysis of survival rates of untreated
patients in randomized clinical trials of hepatocellular carcinoma.
Hepatology. 51:1274–1283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pirisi M, Avellini C, Fabris C, Scott C,
Bardus P, Soardo G, Beltrami CA and Bartoli E: Portal vein
thrombosis in hepatocellular carcinoma: Age and sex distribution in
an autopsy study. J Cancer Res Clin Oncol. 124:397–400. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Costentin CE, Ferrone CR, Arellano RS,
Ganguli S, Hong TS and Zhu AX: Hepatocellular carcinoma with
macrovascular invasion: Defining the optimal treatment strategy.
Liver Cancer. 6:360–374. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hasegawa K, Kokudo N, Makuuchi M, Izumi N,
Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, et al:
Comparison of resection and ablation for hepatocellular carcinoma:
A cohort study based on a Japanese nationwide survey. J Hepatol.
58:724–729. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Murakami T, Ishimaru H, Sakamoto I, Uetani
M, Matsuoka Y, Daikoku M, Honda S, Koshiishi T and Fujimoto T:
Percutaneous radiofrequency ablation and transcatheter arterial
chemoembolization for hypervascular hepatocellular carcinoma: Rate
and risk factors for local recurrence. Cardiovasc Intervent Radiol.
30:696–704. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Llovet JM, Real MI, Montaña X, Planas R,
Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, et al
Barcelona Liver Cancer Group, : Arterial embolisation or
chemoembolisation versus symptomatic treatment in patients with
unresectable hepatocellular carcinoma: A randomised controlled
trial. Lancet. 359:1734–1739. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wakiyama S, Matsumoto M, Haruki K, Gocho
T, Sakamoto T, Shiba H, Futagawa Y, Ishida Y and Yanaga K: Clinical
features and outcome of surgical patients with non-B non-C
hepatocellular carcinoma. Anticancer Res. 37:3207–3213.
2017.PubMed/NCBI
|
|
31
|
Piscaglia F, Svegliati-Baroni G, Barchetti
A, Pecorelli A, Marinelli S, Tiribelli C and Bellentani S;
HCC-NAFLD Italian Study Group, : Clinical patterns of
hepatocellular carcinoma in nonalcoholic fatty liver disease: A
multicenter prospective study. Hepatology. 63:827–838. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jun TW, Yeh ML, Yang JD, Chen VL, Nguyen
P, Giama NH, Huang CF, Hsing AW, Dai CY, Huang JF, et al: More
advanced disease and worse survival in cryptogenic compared to
viral hepatocellular carcinoma. Liver Int. 38:895–902. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mohsen W, Rodov M, Prakoso E, Charlton B,
Bowen DG, Koorey DJ, Shackel NA, McCaughan GW and Strasser SI:
Patients with non-viral liver disease have a greater tumor burden
and less curative treatment options when diagnosed with
hepatocellular carcinoma. World J Gastroenterol. 23:2763–2770.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kimura T, Kobayashi A, Tanaka N, Sano K,
Komatsu M, Fujimori N, Yamazaki T, Shibata S, Ichikawa Y, Joshita
S, et al: Clinicopathological characteristics of non-B non-C
hepatocellular carcinoma without past hepatitis B virus infection.
Hepatol Res. 47:405–418. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liang KH, Yang PC and Yeh CT: Genotyping
the GALNT14 gene by joint analysis of two linked single nucleotide
polymorphisms using liver tissues for clinical and geographical
comparisons. Oncol Lett. 8:2215–2220. 2014. View Article : Google Scholar : PubMed/NCBI
|
